Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$14.91M+0.30%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alison Moore
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 146
- Beta
- 2.53
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -5.99
Financials
Revenue
$14.91M+0.3%Net Income
$-12.01M-935.4%EBITDA
$-10.79M-499.0%Free Cash Flow
$-10.54MEPS (diluted)
$-0.13-533.3%Shares Outstanding (diluted)
91.05M+116.1%Operating Expenses
$22.63MCash & Debt
$54.92MReturn of Capital
$0.00Revenue by Segment (annual)
$70.39MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $70.39M | $-43.97M | $-0.50 |
| 2024 | $59.34M | $-65.28M | $-0.89 |
| 2023 | $70.14M | $-76.24M | $-1.12 |
| 2022 | $138.59M | $-33.59M | $-0.51 |
| 2021 | $104.75M | $-21.28M | $-0.33 |
| 2020 | $69.06M | $-24.01M | $-0.40 |
| 2019 | $68.46M | $-11.94M | $-0.21 |
| 2018 | $60.59M | $-10.88M | $-0.21 |
| 2017 | $50.02M | $-23.00M | $-0.50 |
| 2016 | $48.84M | $-8.56M | $-0.21 |
| 2015 | $41.80M | $-7.58M | $-0.19 |
| 2014 | $35.31M | $-19.07M | $-0.50 |
| 2013 | $31.92M | $-41.30M | $-1.08 |
| 2012 | $88.30M | $-30.86M | $-0.84 |
Valuation
CDXShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
20-86.05%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·8d ago·Negative
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis , Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform.
View source ↗ - Newsglobenewswire.com·40d ago·Negative
Codexis to Participate in Cantor Global Healthcare Conference 2026 REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York.
View source ↗ - Newszacks.com·52d ago·Positive
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock? Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·55d ago·Negative
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.16 per share a year ago.
View source ↗ - Newsmarketbeat.com·55d ago·Negative
Codexis Q2 Earnings Call Highlights Codexis NASDAQ: CDXS reported second-quarter 2026 revenue of $14.9 million, compared with $15.3 million in the prior-year period, as the company highlighted improved performance in its biocatalytic enzyme business and continued development of its ECO Synthesis platform for siRNA manufacturing.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.09 per share
Typical surprise +5.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.13 vs $-0.14beat
- Thu, May 7$-0.10 vs $-0.11beat
- Wed, Mar 11$0.11 vs $0.01beat
- Thu, Nov 6$-0.22 vs $-0.15miss
- Wed, Aug 13$-0.16 vs $-0.17beat
- Wed, May 14$-0.25 vs $-0.20miss
Estimates and results for CDXS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CDXS officers and directors.
- Bought
- $9.7m
- Sold
- $5.7m
34 trades
27 trades
- De Vre Raymondsold
- Lutz Stefansold
- Lutz Stefansold
- Erbez Georgiasold
- Moore Alisonsold
- Lutz Stefansold
- Opaleye Management Inc.sold
- Opaleye Management Inc.sold
39 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lamar Seeligson Smithhouse · TX21 · disclosed May 8, 2018 (32d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.